Nature:混合搭配新冠疫苗可引发有效的免疫反应

一项涉及 663 名参与者的试验的初步结果已经发布,该试验接受了混合时间表的 COVID-19 疫苗品牌。接受第一剂阿斯利康 (AstraZeneca) 疫苗的参与者在至少 8 周后接受辉瑞 (Pfizer) 疫苗的第二剂疫苗。

第 2 剂接种后产生的抗体水平高于第 1 剂接种后产生的抗体水平。与阿斯利康 COVID-19 疫苗的标准 2 剂疗程相比,产生的免疫反应也更强。混合方案所报告的副作用与接受相同品牌方案的患者所经历的副作用相似。这与英国的一项类似研究形成鲜明对比,该研究显示混合接种 COVID-19 疫苗后常见副作用的报告较多。

要阅读全文,请参阅以下链接:

Nature:混合搭配新冠疫苗可引发有效的免疫反应

 

 

 


Raising Children Network - new COVID-19 vaccination: pregnancy and breastfeeding resource

MVEC 与 育儿网 to develop a new resource focused on providing COVID-19 vaccine recommendations for women who are pregnant, breastfeeding or planning pregnancy.

To view this article follow the link below:

COVID-19 vaccination: pregnancy and breastfeeding

Further information on vaccines for pregnant and breastfeeding women can be found via our immunisation reference pages below:

MVEC:怀孕期孕妇疫苗接种

MVEC:母乳喂养和免疫接种

 

 


BBC News: Covid: Pfizer and AstraZeneca jabs work against Indian variant - study

A study conducted by Public Health England (PHE) has shown that either of the Pfizer or AstraZeneca COVID-19 vaccine brands are highly effective against the COVID-19 Indian strain. Two weeks after the administration of dose 2, the Pfizer vaccine was found to be 88% effective at stopping symptomatic disease and the AstraZeneca vaccine was 60% effective.

The effectiveness of only 1 dose of either brand was reduced to 33%, highlighting the importance of administering both doses.

要了解更多信息,请点击以下链接:

BBC News: Covid: Pfizer and AstraZeneca jabs work against Indian variant - study


WHO: COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) reviews cases of mild myocarditis reported with COVID-19 mRNA vaccines

The WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee has released a statement following the review of a small number of cases of myocarditis reported in individuals who have received COVID-19 mRNA vaccines.

Cases have predominantly been reported in adolescents and young adults, with a typical symptom onset occurring within 4 days of vaccination. Reports were more common following receipt of a second dose of the vaccine. GACVS notes that most cases of myocarditis appear to be mild.

The COVID-19 subcommittee reiterates that the benefit of vaccination in reducing deaths and hospitalisations due to COVID-19 disease outweighs potential risk of vaccine side effects.

要阅读更多信息,请点击以下链接:

WHO: COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) reviews cases of mild myocarditis reported with COVID-19 mRNA vaccines

 


Joint statement from ATAGI and THANZ on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of COVID-19 Vaccine AstraZeneca

ATAGI and the Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) have released a joint statement surrounding the administration of COVID-19 AstraZeneca and 血栓形成伴血小板减少症候群 (TTS).

Following close monitoring of local and international data it has been noted that the risk of TTS is not likely to be increased in people who:

  • Have a history of blood clots in typical sites
  • Have an increased clotting tendency that is not immune mediated
  • Have a family history of blood clots
  • Have a history of ischaemic heart disease
  • Currently have or has a history of thrombocytopenia
  • Are receiving anticoagulation therapy

Comirnaty™ is the preferred COVID-19 vaccine for people who:

  • Have a history of idiopathic splanchnic vein thrombosis
  • Have a history of antiphospholipid syndrome with thrombosis
  • Individuals < 50 years of age
  • Have a history of cerebral venous sinus thrombosis (CVST)
  • Have a history of heparin-induced thrombocytopenia (HIT)
  • Have a contraindication to COVID-19 AstraZeneca (including anaphylaxis to a previous dose or anaphylaxis to a component of COVID-19 AstraZeneca, TTS occurring after a dose of COVID-19 AstraZeneca or other serious adverse event following receipt of COVID-19 AstraZeneca)

要阅读该声明全文,请参阅以下链接:

Joint statement from ATAGI and THANZ on Thrombosis with Thrombocytopenia Syndrome (TTS) and the use of COVID-19 Vaccine AstraZeneca

 

 


ABC news: Multilingual women are countering vaccine hesitancy in Victoria's culturally diverse communities

In an effort to improve communication and address vaccine misinformation within culturally diverse communities, the Victorian Department of Health has partnered with the Multicultural Centre for Women's Health and other women's health organisations to deliver a range of information in various languages. Multilingual health educators will be actively engaging within the community by doorknocking public housing, holding online education sessions and answering questions about COVID-19 vaccines, the virus and other health related issues.

To read more about this program follow the link below:

ABC news: Multilingual women are countering vaccine hesitancy in Victoria's culturally diverse communities


The Guardian: Vaccinate vulnerable global poor before children in rich countries, WHO says

The World Health Organization's director-general, Tedros Adhanom, has urged wealthy countries to donate COVID-19 vaccines to poorer nations.

Of the 1.4 billion doses of COVID-19 vaccines administered globally, 44% of those have been administered in high-income countries. Only 0.3% of vaccines have reached the 29 lowest income countries, where 9% of the world's population call home. The WHO has warned that this inequity in vaccine access could result in 2021 experiencing more death than in the first year of the pandemic. With wealthy countries now looking to vaccinate adolescents and children, the WHO are encouraging these countries to instead donate their vaccines through COVAX. This would allow poorer nations to access vaccines and protect their healthcare workers and vulnerable priority groups.

要了解更多信息,请点击以下链接:

The Guardian: Vaccinate vulnerable global poor before children in rich countries, WHO says

 


New immunisation reference page: COVID-19 vaccination in children

COVID-19 infections have generally produced more severe disease outcomes in adults and the older population, with children generally experiencing milder symptoms. For this reason, initial COVID-19 vaccine clinical trials and vaccine rollouts focused on the adult population.  However, it is recognised that in order to achieve herd immunity within the community, the vaccination of children needs to be considered.

Our new reference page outlines the importance of conducting paediatric focused COVID-19 vaccine clinical trials and summarises the trials that are currently underway.

要阅读更多信息,请点击以下链接:

MVEC: COVID-19 vaccination in children

 


澳大利亚科学院 - 免疫科学:问题与解答

澳大利亚科学院发布了最新版本的 免疫科学 - 问题与解答。 开发此资源的目的是帮助了解疫苗接种背后的科学过程,并鼓励人们对 COVID-19 和其他疾病疫苗的信任。

主题包括:

  • 什么是免疫接种?
  • 疫苗里有什么?
  • 谁受益于疫苗?
  • 疫苗安全吗?
  • 疫苗接种的未来会怎样?

您可以通过以下链接在线查看此资源:

澳大利亚科学院 - 免疫科学:问题与解答

 


Provisional determination granted to Pfizer in relation to COVID 19 vaccine, COMIRNATY - for use in individuals 12 years of age and older

The Therapeutic Goods Administration (TGA) has granted provisional determination to Pfizer's COVID-19 vaccine, Comirnaty™ as part of an application process to lower the approved age limit of vaccine administration from 16 years and above, to individuals aged 12 years and above.

Provisional determination is the first step in the provisional registration pathway. The provisional pathway for registration provides a formal and transparent mechanism for speeding up the registration of promising new medicines based on preliminary clinical data. Having provisional determination does not mean that provisional registration will be granted.

要阅读更多信息,请点击以下链接:

Provisional determination granted to Pfizer in relation to COVID 19 vaccine, COMIRNATY - for use in individuals 12 years of age and older